iSpecimen Inc. (ISPC) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Medical - Diagnostics & Research
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.19
↓-77% vs avg
5yr avg: 0.83
30Y Low0.4·High2.1
ROE
↑
-327.8%
↑-22% vs avg
5yr avg: -269.4%
30Y Low-328%·High-41%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ISPC Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
iSpecimen Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $710973 | $1M | $2M | $5M | $12M | $64M | — | — | — |
| Enterprise Value | $-5901064 | $-5415392 | $324593 | $2M | $-2962363 | $40M | — | — | — |
| P/E Ratio → | -0.06 | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.37 | 0.62 | 0.20 | 0.46 | 1.17 | 5.73 | — | — | — |
| P/B Ratio | 0.19 | 0.39 | 0.57 | 0.46 | 0.60 | 2.14 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ISPC EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -2.81 | 0.03 | 0.24 | -0.28 | 3.55 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
ISPC Profitability
Margins and return-on-capital ratios measuring operating efficiency
iSpecimen Inc. earns an operating margin of -465.4%. Operating margins have compressed from -112.5% to -465.4% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -327.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 1.2% | 1.2% | 42.9% | 51.4% | 54.3% | 52.9% | 56.2% | 50.5% | 46.2% |
| Operating Margin | -465.4% | -465.4% | -137.0% | -112.5% | -97.9% | -53.2% | -29.4% | -90.3% | -76.4% |
| Net Profit Margin | -543.7% | -543.7% | -134.5% | -111.8% | -98.5% | -80.5% | -56.8% | -110.0% | -121.7% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -327.8% | -327.8% | -191.5% | -73.9% | -40.9% | -713.1% | — | — | — |
| ROA | -111.1% | -111.1% | -99.3% | -54.9% | -34.0% | -42.7% | -89.3% | -114.5% | -132.2% |
| ROIC | — | — | -204.4% | -131.1% | -143.3% | — | — | — | — |
| ROCE | -261.0% | -261.0% | -190.7% | -74.2% | -38.0% | -68.5% | — | — | — |
ISPC Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $7M exceeds total debt of $268798, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.09 | 0.09 | 0.09 | 0.02 | 0.01 | 0.11 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -2.14 | -0.47 | -0.22 | -0.74 | -0.82 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -5375.89 | -5375.89 | -57.58 | -47.09 | -41.88 | -3.26 | -1.22 | -1.83 | -3.51 |
Net cash position: cash ($7M) exceeds total debt ($268798)
ISPC Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.12x means iSpecimen Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 1.36x to 1.12x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.12 | 1.12 | 0.62 | 1.36 | 4.60 | 13.15 | 0.16 | 0.10 | 0.20 |
| Quick Ratio | 1.12 | 1.12 | 0.62 | 1.36 | 4.60 | 13.15 | 0.16 | 0.10 | 0.20 |
| Cash Ratio | 1.10 | 1.10 | 0.33 | 0.83 | 3.58 | 11.07 | 0.03 | 0.00 | 0.10 |
| Asset Turnover | — | 0.20 | 0.99 | 0.63 | 0.42 | 0.31 | 1.32 | 1.02 | 1.09 |
| Inventory Turnover | — | — | — | — | — | — | — | 38.75 | 49.96 |
| Days Sales Outstanding | — | 9.14 | 56.75 | 108.12 | 137.75 | 160.04 | 105.19 | 118.26 | 85.20 |
ISPC Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
iSpecimen Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $115062 | $17771 | $11302 | $11055 | $10216 | $1170 | $1170 | $1171 |
Peer Comparison
Compare ISPC with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ISPCYou | $710973 | -0.1 | — | — | 1.2% | -465.4% | -327.8% | — | — |
 BRLT | $226M | -5.7 | 122.9 | 39.3 | 57.5% | -1.2% | -3.8% | -9.7% | 25.3 |
 MEDP | $12B | 27.7 | 21.1 | 17.8 | 30.1% | 21.1% | 70.2% | 154.9% | 0.4 |
 BLFS | $1B | -88.2 | — | 101.2 | 64.6% | -12.6% | -3.4% | -2.8% | — |
 ICLR | $10B | 13.1 | 7.9 | 8.5 | 29.4% | 13.3% | 8.4% | 6.5% | 2.3 |
 CRL | $9B | -61.0 | 12.7 | 16.9 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
 LMAT | $2B | 42.8 | 33.4 | 33.0 | 71.5% | 27.2% | 15.8% | 9.7% | 2.4 |
 QDEL | $737M | -0.6 | — | — | 46.7% | -33.7% | -46.1% | -13.6% | — |
 NTRA | $28B | -127.8 | — | 252.3 | 64.8% | -13.4% | -14.3% | -36.1% | — |
 TMO | $173B | 26.2 | 18.7 | 27.5 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
 DHR | $121B | 34.0 | 17.8 | 23.0 | 60.9% | 20.9% | 7.1% | 5.9% | 2.4 |
| Healthcare Median | — | 22.2 | 14.4 | 18.6 | 63.9% | -5.1% | -33.9% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
See ISPC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ISPC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ISPC vs BRLT
Side-by-side business, growth, and profitability comparison vs Brilliant Earth Group, Inc..
Start ComparisonISPC — Frequently Asked Questions
Quick answers to the most common questions about buying ISPC stock.
What is iSpecimen Inc.'s P/E ratio?
iSpecimen Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
What is iSpecimen Inc.'s ROE?
iSpecimen Inc.'s return on equity (ROE) is -327.8%. The historical average is -158.5%.
Is ISPC stock overvalued?
Based on historical data, iSpecimen Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are iSpecimen Inc.'s profit margins?
iSpecimen Inc. has 1.2% gross margin and -465.4% operating margin.